Effects of Resistant Starch Diet on the Gut Microbiome in Chronic Kidney Disease
2 other identifiers
interventional
19
1 country
1
Brief Summary
The investigators want to learn more about how to help people who have chronic kidney disease (CKD). This study will increase the investigators understanding of how diet affects factors that can slow the progression of kidney disease. The investigators are asking 30 adults and 30 children with stage 3 CKD to be part of this study. Participants will supplement their diet with resistant starch for two weeks. The investigators anticipate that the resistant starch will change the bacteria in the intestines to a more beneficial type of bacteria. The investigators will measure a product of these beneficial bacteria called butyrate. The investigators will also determine changes in the gut bacteria and products of the bacteria in the blood.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 14, 2017
CompletedFirst Posted
Study publicly available on registry
November 29, 2017
CompletedStudy Start
First participant enrolled
February 12, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedMarch 7, 2025
March 1, 2025
6.9 years
November 14, 2017
March 4, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of subjects that consume at least 90% of the dietary resistant starch (RS).
Packaging will be returned by the subject at the end of the time period in order to determine compliance.
2 weeks
Study Arms (1)
Resistant Starch
EXPERIMENTALIntervention: Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose of Hi-Maze 260 or "High RS Gummy Chews" in the morning and the other half dose in the evening Adult participants are asked to introduce in their diet 30 grams of high RS supplement each day of the diet period (2 weeks). Children of age included between 5 and 9 years are asked to introduce in their diet 10 grams of high RS supplement each day of the diet period (2 weeks). Children of age included between 10 and 17 years are asked to introduce in their diet 15 grams of high RS supplement each day of the diet period (2 weeks).
Interventions
Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or "High RS Gummy Chews" in the morning and the other half dose (one bag) in the evening.
Eligibility Criteria
You may qualify if:
- Adult
- Between the ages of 18 and 85 years old
- Glomerular filtration rate estimated by creatinine clearance (eGFR Cr):between 59 and 30 ml/min for stage 3 CKD patients
- Urine protein \< 1 gram per day by 24-hour protein collection or urine protein-to-creatinine ratio \<1 gram/gram or urine microalbumin to creatinine concentration less than 1000 mg/g.
- Children
- Between the ages of 5 and 17 years
- eGFR Cr between 30 and 59 (stage 3 CKD) using the revised Schwartz equation.
- Urine protein \< 1 gram per day by 24-hour protein collection or urine protein-to-creatinine ratio \<1 gram/gram.
You may not qualify if:
- Adult
- Age older than 85 years
- eGFR Cr \> 59 ml/min or \< 30 ml/min
- History of renal transplant
- Subject with diabetes (as defined by patient report, taking medications for the treatment of diabetes or as reported in the medical record)
- Use of antibiotics within 1 month
- Use of laxatives within 1 month
- Inflammatory bowel disease
- Irritable bowel syndrome
- Colorectal cancer
- Surgically removed bowel or presence of an ostomy
- Pregnancy
- Inability to obtain written informed consent
- Constipation
- Diarrhea
- +12 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Arkansaslead
- National Institutes of Health (NIH)collaborator
- National Institute of General Medical Sciences (NIGMS)collaborator
Study Sites (1)
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
John M Arthur, MD, Ph.D.
University of Arkansas
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 14, 2017
First Posted
November 29, 2017
Study Start
February 12, 2018
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
March 7, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share